Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ARMS Clear all
Withdrawn Phase 4 Interventional

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
View directory record Official record
Conditions
Hepatitis C
Interventions
Elbasvir/grazoprevir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

NCT04461600
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
AL101
Drug
Lead sponsor
Ayala Pharmaceuticals, Inc,
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of CTP-543 in Healthy Volunteers

NCT03880136
View directory record Official record
Conditions
Healthy
Interventions
CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

NCT00685698
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
TG-873870 (Nemonoxacin)
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Montebello, California • Pasadena, California • Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM

NCT01546675
View directory record Official record
Conditions
Traumatic Amputation of Arm
Interventions
Skeletal Stabilization
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

NCT04099836
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 21, 2026, 5:35 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

NCT06126042
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Test Product, Reference product, Reference Medicinal Product
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

NCT00001083
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 5:35 AM EDT
Withdrawn Not applicable Interventional

Pneumatic Compression Treatment For Upper Extremity Acquired Lymphedema

NCT00951067
View directory record Official record
Conditions
Lymphedema
Interventions
Exercise, Elevation, and Compression Garment, E0650 PCD with non-sequential waveform, E0651 PCD with sequential, non-gradient waveform, E0652 PCD with sequential, gradient waveform, E0652 PCD with peristaltic pulse waveform
Other · Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients

NCT06466161
View directory record Official record
Conditions
Hypertension in Pregnancy, Hypertension, Obesity
Interventions
Upper Arm Cylindrical Blood Pressure Cuff, Forearm Conical Blood Pressure Cuff
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

NCT06627270
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma, Oral Cancer, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Metronidazole, Chlorhexidine
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

NCT06125951
View directory record Official record
Conditions
Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions
Xanamem, Placebo
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

NCT01991457
View directory record Official record
Conditions
Adult Lymphoblastic Lymphoma
Interventions
Fludarabine, Total Body Irradiation
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
17
States / cities
Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

NCT00775203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

NCT02698566
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 21, 2026, 5:35 AM EDT
Suspended Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727
View directory record Official record
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of the Buzzy System on Pain and Fear Reduction in Elbow Fracture Pin Removal

NCT07520851
View directory record Official record
Conditions
Elbow Fractures
Interventions
Flash Cards, Buzzy Ice pack
Other · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
3 Years to 10 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

NCT02537431
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Cast or Operation for Medial Epicondyle Fracture Treatment in Children

NCT05131672
View directory record Official record
Conditions
Fracture Elbow
Interventions
open reduction and internal fixation (ORIF), cast immobilization
Procedure
Lead sponsor
Joseph Janicki
Other
Eligibility
7 Years to 17 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 5:35 AM EDT